Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomised trials

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 391-398

  Valle, J W ^a   Furuse, J ^b   Jitlal, M ^c   Beare, S ^c   Mizuno, N ^d   Wasan, H ^e   Bridgewater, J ^c   Okusaka, T ^f  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Biliary tract cancer; Cholangiocarcinoma; Cisplatin; Gallbladder cancer; Gemcitabine

Indexed keywords

CISPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADVANCED CANCER; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; GALLBLADDER CANCER; HUMAN; JAPANESE; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED KINGDOM; ANALOGS AND DERIVATIVES; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DISEASE FREE SURVIVAL; INTRAHEPATIC BILE DUCT; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84893354743     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt540     Document Type: Article

References (18)

1. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-1667.
2. Randi G, Malvezzi M, Levi F et al. Epidemiology of biliary tract cancers: an update. Ann Oncol 2009; 20: 146-159.
3. Matsuda T, Marugame T. International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from Cancer Incidence in Five Continents Vol. VIII. Jpn J Clin Oncol 2007; 37: 74-75.
4. Taylor-Robinson SD, Toledano MB, Arora S et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48: 816-820.
5. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357.
6. Khan SA, Taylor-Robinson SD, Toledano MB et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806-813.
7. Anderson CD, Pinson CW, Berlin J et al. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004; 9: 43-57.
8. DeOliveira ML, Cunningham SC, Cameron JL et al. Cholangiocarcinoma: thirtyone-year experience with 564 patients at a single institution. Ann Surg 2007; 245: 755-762.
9. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
10. Sharma A, Dwary AD, Mohanti BK et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010; 28: 4581-4586.
11. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96: 896-902.
12. Valle JW, Wasan H, Johnson P et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study-the UK ABC-01 Study. Br J Cancer 2009; 101: 621-627.
13. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
14. Okusaka T, Nakachi K, Fukutomi A et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474.
15. Furuse J, Okusaka T, Bridgewater J et al. Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Crit Rev Oncol Hematol 2011; 80: 31-39.
16. Walter T, Horgan AM, McNamara M et al. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer 2012; 49: 329-35.
17. Bridgewater J, Palmer D, Cunningham D et al. Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer 2012; 49: 1511.
18. Roth JA, Carlson JJ. Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer. J Gastrointest Cancer 2012; 43: 215-223.